Last Week in Event SPACE - Astellas, Celltrion, Renesas, AWE, Viva, Kushikatsu
Last week, Astellas Pharma Inc (4503 JP)'s latest buyback may impact the stock; KOSDAQ 150 names expected to benefit as Celltrion Inc (068270 KS)...
417 Views
Astellas (4503 JP) Buyback - How It Stacks Up Against Past Buybacks
A small note about the buyback. There is more here than meets the eye.Today, Astellas Pharma Inc (4503 JP)announced a buyback program to repurchase...
365 Views
Astellas (4503) - PROSPER Data Revives Value Story
For a drug that was targeted to hit US$6~8bil in sales, last year’s US$2.3bil revenue figure for Xtandi was decidedly below par. With the start of...
314 Views
Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib
News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...
347 Views
Takeda - Brigantinib Gets FDA Approval
Earlier this year, Takeda Pharmaceutical Co Ltd (4502 JP) spent US$4bil on Ariad Pharmaceuticals Inc (ARIA US), thereby acquiring a company with a...
416 Views